Sign In
About ASHM | Careers | Your Cart Shoppint Cart
Skip Navigation LinksASHM Internet Home > Register now to join in the conversation with leading experts in Viral Hepatitis

Register now to join in the conversation with leading experts in Viral Hepatitis

Conference; Update; News |
Co-infection; Hepatitis B; Hepatitis C |
Aboriginal Torres Strait Islander Health Worker; Allied Health; ASHM Members; Corrections Law Enforcement; Dentists; Emergency Services Providers; Government Policy; Laboratory Testing; Nurses; Pharmaceutical Industry; Prescribers; Research; Specialists; Students Trainees |
  |
  |
ASHM |
  |
  |
With three months leading to the 10th Australasian Viral Hepatitis 2016 Conference held in the Gold Coast, Queensland from 29 September to 1 October, there’s no better time to plan towards attending this highly valuable educational opportunity.

​​​VH Conference Banner.jpg

Register today ​and take advantage of early bird fees ending Sunday 31 July 2016.


July 2016:  With three months leading to the 10th Australasian Viral Hepatitis 2016 Conference held in the Gold Coast, Queensland from 29 September to 1 October, there's no better time to plan towards attending this highly valuable educational opportunity – and to join a diverse delegation who include Viral Hepatitis specialists, gastroenterologists, physicians, General Practitioners, addiction medicine specialists, drug and alcohol workers, nurses, social workers, community workers, educators, pharmaceutical company representatives, basic scientists, Infectious Disease specialists, researchers, National/State & Territory Government agency personnel, NGO personnel, Regional/Area Health Authority personnel, and People Living with Viral Hepatitis.
 
It is a crucial year for HCV treatment and management – a unique moment in history to reduce the burden of HCV in Australia, and never before has there been a more important conference to attend.

With World Hepatitis Day on July 28, now recognized as one of only a few designated world health days, viral hepatitis is globally  responsible for 1.4 million deaths yearly and is the 8th highest cause of mortality globally, mainly due to HBV and HCV infection with the remainder from hepatitis A and E. 

Scott Bowden, one co-committee member of the conference, announces that one part of the program themed on Basic Science focuses on the elimination of viral hepatitis as a public health threat and how this can be achieved. "Will the new HCV antivirals be able to control HCV without a vaccine? We can reduce liver disease progression due to HBV infection but what can we do to eliminate the virus? The contribution of the other agents of viral hepatitis, HAV, HDV and HEV to public health will also be considered." 

Hear and learn from a multidisciplinary range of key speakers and panellists leading the conversation in their respective field of viral hepatitis clinical management and care, epidemiology, public health, community and social research – with highlighted keynote speakers pictured above) including:
 
Alexander Ploss (PhD, Assistant Professor, Department of Molecular Biology, Princeton University) who discusses his pioneering research and provides his opinions on the greatest unmet needs in hepatitis C research that could one day affect treatment.
 
Kate Seear (ARC DECRA Fellow and Senior Lecturer in Law at Monash University) who considers the role that the law and legal practices play in shaping hepatitis C transmission and the nature and scale of hepatitis C epidemics in Hepatitis transmission and prevention: Exploring the role that the law plays in shaping blood borne virus epidemics.
 
Peter Revill (Senior Medical Scientist, Victorian Infectious Diseases Reference Laboratory, Doherty Institute, Melbourne, VIC) who presents Global Strategies are required to cure and eliminate HBV with a proposal of the establishment of an International Coalition to Eliminate Hepatitis B work group, to promote awareness and education as well as to drive changes in governmental policy and ensure funds are channelled to HBV cure research and drug development.
 
Greg Dore (Head of Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia, and Infectious Diseases Physician, St Vincent's Hospital, Sydney) has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care and public health policy for 20 years. His paper on The new HCV treatment era in Australia: early lessons focuses on direct acting antiviral (DAA) scale-up data, including regimen and prescriber patterns, discussion of potential gaps in early coverage, strategies for maintaining the momentum, and potential impact on population-level disease burden.

 
Both medical and non-clinical professionals working in the sector are also welcome to attend pre-conference associated event workshops held Wednesday 28 and Thursday 29 September.


Visit the conference website for more information on speakers, accommodation options, the program, and registration types and rates (tax deductible for most attendees).


Register today ​and take advantage of early bird fees ending Sunday 31 July 2016.

Please enter a valid E-mail.
This must match your colleagues E-mail.
Please enter your name.
Please enter a valid email.
This must match your email.